RTTNews

Pasithea Announces Strong Preclinical Results For PAS-004 In Inflammatory Disease Model

(RTTNews) – Pasithea Therapeutics Corp. (KTTA) announced new preclinical data demonstrating that PAS-004 provides superior inhibition of ETS2-driven inflammatory responses compared to selumetinib in a human macrophage model of chronic inflammation that mimics the inflammatory milieu seen in inflammatory bowel

Pasithea Announces Strong Preclinical Results For PAS-004 In Inflammatory Disease Model Read More »